July 13, 2017 08:00 AM EDT
People

Ex-GSK CEO An­drew Wit­ty goes biotech, tak­ing a board seat at G1

John Carroll

Editor & Founder

An­drew Wit­ty and G1 CEO Mark Vel­le­ca File Pho­to

An­drew Wit­ty may have just stepped out of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

A service from the Financial Times